Abstract
According to an exploratory analysis of data from the POSEIDON trial, patients with non–small cell lung cancer and KRAS, STK11, or KEAP1 mutations fared better on the three-drug combination of tremelimumab and durvalumab plus chemotherapy compared with chemotherapy alone. However, small sample sizes precluded any definitive interpretation of the findings.
©2022 American Association for Cancer Research
2022
American Association for Cancer Research
You do not currently have access to this content.